Meridian Bioscience Receives FDA Clearance for New Legionella Test
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance from the U.S. Food and Drug Administration for TRU Legionella™, a new rapid assay for detection of legionellosis. TRU Legionella is a rapid lateral flow device that provides optimized detection of Legionella pneumophila serogroup 1 that is most commonly associated with Legionnaire's disease. Suspected infection is characterized by non-specific upper respiratory symptoms. The disease accounts for almost 100,000 cases per year in the U.S., and it is estimated that 10,000 to 20,000 people are hospitalized with Legionnaire's disease. However, many infections are not diagnosed due to poor diagnostic options and these numbers may be higher.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.